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O!$ctives. Our aim was to evaluate the benefits and risks of 
administering propafeaone before electrical defibrillation for 
chronic atria1 fibrillation. 
Background. fn this eontext, an antiarrhythmic drug- 
&bough potentially useful in preventing early recurrence of 
arrhythmia-could adversely affect the defibrillation threshold 
and reduce the cardioversion success rate. 
rvletlrads. We randomly assigned 100 patients with chronic 
atrial fibrilhiion to oral treatment with either phuebo (51 pa- 
tients) or 750 mg/day of propafenone (49 patients) for 48 b before 
adm~~~strat~on of direct current shoch. After successful cardin- 
version, ah patients received propafenone therapy and were 
fGtiOW& Up fOl+48 b. 
&st&. Before defihril!ation, three patients in the propafenone 
group (6.1%) had reversion to sinus rhythm and one bad sus- 
taiued vcatricular tachycardia. Shock efficacy (82.4% vs. 84.4%) 
and the cumulative etfective energv (395 f 25g vs. 421 9 236 J) 
were not dikrent between the placebo and propafenone groups. In 
the propzfenone group, 11 patients had their arrhythmia trans- 
formed into atria1 Rutter and required a lower energy level for 
arrhythmia conversion than did the other patients with continued 
atria1 fibrillation (245 2 197 vs. 493 2 215 J, p < 0.01 j; the latter 
patients showed a trend (p c 0.10) toward higher energy reqoire- 
ments than that of patients who received placebo. The incidence of 
asymptomatic bradyarrhythmias was higher in the propafenone 
group (2g.9% vs. 7.l.%, p c 0.02), but more patients who received 
placebo had early recurrence of atria1 fibrillation (16.7% vs O%, 
p < QJE). Two days after cardioversion, more patients given 
propafenone (73.5% vs. 52.%, p c 0.05) were discharged from the 
hospital with sinus rhythm. During the in-hospitai stay, propaw 
fenone was withdrawn from six patients (6.6%) because of side 
effects. 
C~ncZ~sio~ts. Propafenone, given before electrirai cardioversion 
for chronic atrial fibrillation does not affect the mean defibrilla- 
tion threshold or the rate of successful arrhythmia couversion. It 
decreases the recurrence of atria1 fibrillation early after shock, 
thus allowing more patients to be discharged from the hospital 
with sinus rhythm. 
{J Am Coil Cardiol1996;28:?t&6) 
It is well established that some antiarrhythmic d;,pgs are useful 
for long-term maintenance of sinus rhythm after electrical 
cardioversion of chronic atrial fibrillation (1,2). Whether the 
antiarrhythmic treatment should be started befcre or after 
enrdioverskm k\s been insu i~~~~~i~~l~ ~~~~~~~~i~~~~t~cl~ ‘There is 
evidence that ar~t~arrhythnl~c drugs may increase the energy 
required for ventricular defibrillation (3-8). This observation 
raises the concern that the same drugs could also increase the 
atria1 defibrillation threshold, thereby reducing the likelihood 
of restoration of sinus rhythm. In addition, ventricular proar- 
rhythmic effects as well as bradyarrhythmias have been de- 
scribed after cardioversion preceded by antiarrhythmic drug 
administration (9,lO). However, some antiarrhythmic agents 
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have been shown to reduce the incidence of supraventricular 
premature beats-possible harbingers of recurrence of atria1 
fibrillation-but whether they actually reduce the recurrence 
of the arrhythmia is an unresolved and largely speculative 
issue. 
There are only a few published studies (9-16) on the effects 
of treatment with antiarrhythmic drugs in patients undergoing 
elective transthoracic cardioversion for chronic atria1 fibrilla- 
tion. No data are a-Tailable on propafenone, a class IC drug 
that has been found useful in treating this arrhythmia (17-20). 
The purpose of the present study was to assess the risk/benefit 
ratio of administering propafenone before attempted cardio- 
version in patients with chronic atria1 fibrillation. 
M&IO& 
Study patients. All patients with chronic (>l month) atria1 
fibrillation scheduled for cardioversion between April 1992 
and March 1994 were considered for the study. ,4 complete 
clinical examination, K&lead electrocardiogram (ECG), 24-h 
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ambulatory ECG (Halter) recording, color Doppler echocar- 
diogram and baseline assessment of renal, hepatic and thyroid 
function were performed. Exclusion criteria were bifascicular 
block, mean daytime ventricular rate ~80 beatsimin in patients 
not receiving digitalis or other drugs depressing atrioventricu- 
lar (AV) node conduction, sinus node dysfunction (sinus 
bradycardia 550 bealsimin, sinus pauses or sinoatrial block 
documented before atrial fibrillation onset), uncontr&ed hy- 
perthyroidism, major hepatic or renal dysfunction, ar,a clinical 
signs of cardiac or respiratory insufficiency. Patients who met 
the prcseding criteria, accepted participation in the study and 
gave written informed consent were considered eligible for the 
trial. 
No study patient had been receiving any class I, Iii or IV 
antiarrhythmic agent for ~5 half-lives or amiodarone for ~3 
months. AI1 patients had had full anticoagulation with warfarin 
or acenocoumarin for ~3 weeks. 
study design. The trial was designed as a single-blind, 
randomized, placebo-controlled study. The study protocol was 
approved by the review board of our institution. 
A regimen in which the drug was administered both before 
and after cardioversion, was compared with a second regimen 
in which the patients received the drug only after the direct 
current (DC) shock. We then sought to assess which of the two 
regimens was preferable with respect to conversion to sinus 
rhythm, energy requirement for cardioversion, postshock ar- 
rhythmias, predischarge maintenance of sinus rhythm and 
untoward effects. 
The patients were prospectively allocated, according to a 
randomization table, to receive propafenone, 750 mg/day 
orally in three divided doses of 300, 150 and 300 mg, or three 
daily doses of placebo (vitamin B, tablets, matching the 
appearance of propafenone tablets). After 48 h the patients 
who still had atria1 fibrillation underwent transthoracic electri- 
cal defibrillation. 
All cardioversions were performed with the patient in the 
fasting state during the morning. Propofol, 100 to 150 mg 
intravenously, was used for anesthesia. A Temtech defibrillator 
(Temtech Ltd., Bangor, Northern Ireland, United Kingdom) 
with hand-held paddle electrodes (7 X 11 cm) was used. The 
paddles were placed in the right upper parasternaf border and 
over the left ventricular apex. Synchronized DC shocks were 
deliver& at increasing energy levels: 100, 200, and 300 J, the 
last administered twice. The procedure was ended after resto- 
ration of sinus rhythm or delivery of two 300-J shocks. A 
rhythm strip was obtained during defibrillation and for 1 min 
thereafter. Then, oscilloscopic monitoriig was continued for 
10 min. A IZlead ECG was recorded immediately before and 
after cardioversion. 
All EC& were independently analyzed in blinded manner 
by two experienced cardiologists. Controversial readings were 
resolved by collegial discussion. Atrial fibrillatiokr was diag- 
nosed by ECG when atrial activity was represeated by small? 
irregular baseline undulations of variable amplitude and con- 
figuration (fwaves) at rates >3SOimin. Partial regularization of 
f waves (fibrillo-flutter) was classified as airhl fibrillation. 
Atria1 flutter was diagnosed when identically recurring regular 
atria1 waves at a rate <350/min (F waves) were present. 
Because the flutter waves may be slowed by class IC drugs, we 
did not set a lower limit for the F wave rate. The following were 
considered arrhythmic complications: severe sinus bradycardia 
(545 beatsimin, lasting >10 s), second-degree sinoatrial block, 
pauses >2 s, junctional rhythm (regular rhythm of 23 beats at 
a rale 60 beal-simin without identifiable P waves), AV block 
of any degree, frequent (2 lO/min) or complex (couplets, runs 
or self-limiting episodes of atria1 fibrillation) atria1 premature 
beats, recurrence of stable atria1 fibrillation, and any number of 
premature ventricular beats. 
After successful cardioversion the patients ;i:lready receiving 
propafenone continued to receive the drug; patients in the 
placebo group were given propafenone, 750 mg/day orally, 
starting with 300 mg 1 h after the procedure. An ECG was 
obtained 24 and 48 h afrer DC shock. In the absence of 
complications, the patients who still had sinus rhythm were 
discharged from the hospital 48 h after cardioversion. 
Statistical analysis. The results were expressed as mean 
value 2 SD. Differences in continuous variables were arzalyzed 
by one-way analysis of variance, aud groups were compared 
with use of the multiple Bonferroni test. Differences its cate- 
goric variables were analyzed by the two-sided Fisher exact test 
or chi-square test, with Yates correction ifneedcd. Recurrence 
curves of atria1 fibrillation in the placebc and propafenone 
groups were compared by the method of Mantel and Cox and 
the risk of relapse of arrhjThmia at each observation time was 
assessed by relative risk analysis (21). The enera necessary fo? 
cardioversion in the placebo and propafenone groups was 
compared by Mann-Whitney U test. All statistical tests were 
performed with tise of BMPD statistical software. A p value 
< 0.05 was considered significant. 
Results 
Patient characteristics, The study group consisted of 100 
patients, 51 assigned to placebo and 49 to propafenone treat- 
ment. The groups were comparable in age, 3&r&r.. ~:+-- 
;veight, left atria1 dimensions, duration of atria1 iib$a&>:~ I& 
underlying heart disease (Table 1 and 2). Twenty-two patients, 
10 in the placebo and 12 in the propafenone group, had had 
previous cardioversion with subsequent recurrence of the 
arrhvthmia; in 17 the arrhythmia had recurred while they were 
receiving an antiarrhythmic drug: quinidine (n = 8): sotalol 
(n = 31, amiodarone (n = & flecainide (n = 2) or low dose 
propafenone (n = 2). 
Quteome before DC shock, Before the scheduted cardio- 
version, no patient in the placebo group and three (6.1%) in 
the propafenone group had conversion to sinus rhythm (p = 
NS). During day 2 of propafenone administration, one patient 
had an episode of sustained ventricular tachycardia, syrnptom- 
atic for presyncope; the arrhythmia subsided before any inter-’ 
vention add the drug was discontinued. 
In I1 patients in the propafenone group, the ,ECG oQtaiFFd,i’. 
immediately before the cardioversion attempt documented the.~! 
,_ 
.” : ,I. .j 
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Table 1. Baseline Characteristics of the Study Patients 
Placebo Propafenone 
Group Group 
(n = 51) (n = 49) 
Age (~4 63.8 -t 10.7 67.3 2 11.2 
Male/female 26!2S 28121 
Body weight (kg) 11 c 17.1 76.9 i- 14 
Left atria1 dimension 46.4 t 7.6 46.4 f 6.3 
(long axis. mm) 
Atria! fibrillation 1.6 f 6.8 9.7 i 18.6 
duration (mo) 
Patients with 10 12 
previous direct 
current shock 
-- 
P 
Value 
0.12 
0.67 
0.92 
0.98 
0.45 
0.72 
Data presented are mean value t SD or number of patients. 
appearance of atria1 flutter (p < 0.01 vs. the placebo group) 
(Fig. 1). The mean rate of F waves was 257 t 52/min. There 
were no cases of 1:I atrioventricular conduction. 
No clinical events or significant FCC modifications were 
observed in the placebo group. 
Cardioversion: efficacy and energy requirements. Sinus 
rhythm was restored in 42 (S2.4%) of the 51 patients given 
placebo and in 38 (S4.4%) of the 45 patients given 
propafenone who underwent DC shock (p = NS). With 
inclusion of the three patients with chemical cardioversion, 
sinus rhythm was obtained in 41 (83.7%) of the 49 patients in 
the propafenone group. There was no difference in cardiover- 
sion success rate between patients undergoing their first car- 
dioversion (62 [83.8%] of 74) and those undergoing their 
second cardioversion (18 [Sl.S%] of 22). 
No significant difference emerged between the two treat- 
ment groups in the number of patients with conversion or the 
cumulative co.wersion rate at each energy level (Fig. 2). The 
cumulative energy required for cardioversion was 395 + 258 J 
in the placebo and 421 rt: 236 J in the propafenone group (p = 
NS). 
In the propafenone group, all 11 patients whose atria1 
fibrillation was transformed into atria1 flutter had successful 
cardioversion, and the cumulative energy required was signif- 
icantly lower than that in the other 34 patients who continued 
to have atria! fibrillation (245 rt: 197 vs. 493 rt 215 J, p < 0.02). 
In these latter patients the cumulative effective energy was 
higher than that in the placebo group (p = < 0.10, NS). Figure 
Table 2. Heart Disease Associated With Atrial Fibrillation in the 
Study Patients* - 
Placebo Group Propafenone Group 
Heart Disease (n = 51) (n = 49) -- 
Hypertensive 16 22 
Valvular 1s 10 
lschemic 4 7 
Cardiomyopathy 3 0 
Idiopathic 13 10 
*There were no significant differences between groups. 
3 compares the number of patients with arrhythmia conversion 
and the cumulative conversion rate at each energy level among 
patients with atrial ffutter or atrial fibrillation in the 
propafenone group and patients given placebo. 
Atrial fibtiIIatIan recurrence. The rate of maintenance of 
sinus rhythm at the predefined observation times after success- 
ful cardioversion in the two treatment groups is shown in 
Figure 4. The curves are significantly divergent in favor of the 
patients pretreated with propafenone (p < 0.01). 
The most relevant finding was that, within 10 min after DC 
shock, no patient given propafenone had recurrence of atrial 
fibrillation, whereas the arrhythmia recurred in seven (16.7%) 
patients given placebo (p = 0.012). 
In the propafenone group the relative risk (RR) of recur- 
rence of atrial fibrillation was significantly lower both at 24 h 
(RR 0.17,95% confidence interval [CI] 0.04 to 0.72, p < 0.01) 
and at 48 h (RR 0.31, CI 0.14 to 0.81, p < 0.05). At this latter 
time, 64.2% of patients with cardioversion in the placebo 
group and 87.8% of propafenone-treated patients with cardio- 
version had sinus rhythm (p < 0.05) (Fig. 4). There was no 
difference in the rate of recurrence of arrhythmia between 
patients undergoing a first cardioversion (13 [21%7 of 62) and 
those with a second cardioversion (4 [22.2%] of 18). 
Of the initial study group, 27 (52.9%) of the 51 patients who 
received placebo and 36 patients (73.5%) who received 
propafenone had sinus rhythtr {p < 0.05). 
Regardless of the protocol, in five of the seven in placebo- 
treated patients whose atrial fibrillation recurred 510 min 
after cardioversion, received an intravenous bolus of 1.5 mg/kg 
body weight of propafenone followed in 5 min by a new DC 
shock. All five had stable sinus rhythm until discharge. For the 
purpose of the study, they were classified in the placebo failure 
group. 
Complications. Table 3 lists the complications that oc- 
curred during the 10 min of ECG monitoring after shock 
delivery. Patients in the placebo group had a significantly 
higher incidence of frequent and complex supraventricular 
premature beats (52.4% vs. 18.4%, p = 0.002). They also had 
a higher incidence of isolated ventricular premature beats 
(13.4% vs. 2.1%, p = NS). No frequent or complexventricular 
arrhythmias were observed in either group. 
The overall incidence of sinus node dysfunction (severe 
sinus bradycardia, sinoatrial block or sinus pauses, junctional 
rhythm) after cardioversion was higher in the propafenone 
than in the placebo group (28.9% vs. 7.1%, p = ~1.017); 
intranodal AV conduction disturbances (first-degree and Mo- 
bitz 1 type secoud-degree AV block) had a similar incidence in 
the two groups (7.1% vs. 10.2%). AI1 the excitation/conduction 
disorders observed during the initial 10 mitt of monitoring were 
asymptomatic. These disorders were typically short-lasting 
except in four patients in the propafenone group: two with 
sinus node dysfunction, one with f&degree AV block (PR 
interval 0.40 s) and one with intranodal second-degree AV 
block. The first two patients, because of persistent brady- 
arrhythmia 48 h after propafenone withdrawal received a 
permanent pacemaker (AA1 and DDD, respectively); in the 
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Figure 1. Twelve-lead electrocardiograms clem- _ Al- 1’6 
onstrating the transformation of atrial fibrilia- , 2 ‘L.--&--h , ( 1 
: I 
tion into atrial flutter by propafenone. A3 Atriai e--.-\rr-.*-y---- ----ra-.--.--- 
fibrillation before treatment. B, After 48 h 
of propafenone therapy. Discrete and regular 
F waves at a rate of 2OO/min are present (ar- 
rowheads), indicating the appearance of slow I WI 
atria1 flutter. F = lead aVF; L = lead a\iZ, R = -Jv--JA/ir--‘lr----j 
lead aVR. 
Jq v ? 
r--4---~~~--i~r----~~ ----ii__ 
patients with intranodal conduction delay propafenane dosage 
was reduced to 450 mgiday. 
During the in-hospital stay after cardioversioil, propafencme 
dosage was reduced in five mcxe patients (three of whom had 
been receiving the drug before cardioversion) because of new 
onset second-degree AV btock (n = I> or QRS widening 
>120 ms (n = 4). The drug was withdrawn because of side 
effects in five pat&n&, two of whom were treated with placebo 
before DC shock. The untoward effects were: presyncope (n = 
I), heart failure (n = 21, asthma (n -- l), first-degree AV block 
of 0.40 s (n = 1). Thus, with inclusion of the patient who had 
ventricular tachycardia before DC shock, propafenone was 
withdrawn in 6 (6.6%) of the 91 patients exposed to it. 
Why an antiarrhykhmic &vg is&~? ek&ical cardiover- 
sion? A brief course of antiarrhythmic drug therapy is fre- 
quentty used in clinicaI practice before cardioversion, but few 
studies have examined whether such a practice is justified in 
terms of risk/benefit ratio. From a theoretic point of view, such 
pretreatment offers at least two advantages: The drug may 
result in chemical cardioversion in some patients-hence, 
avoiding the need for electrical defibrillation-and may ores 
vent early recurrence of the arrhythmia. However, the drug 
could raise the defibrihation threshold and bring about post- 
cardioversion bradyarrhythmias or tachyarrbythmias. 
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-Wpla!Xbct 
apropafenane 
Joules 0 400 200 300 2nd300 
placebo 0 40 47 40 5 
propaf 3 7 14 44 3 
Figure 2. Cumulative percent of patients with cardioversion at each 
energy level in the placebo and propafenone (propaf) groups. The 
patients who had reversion to sinus rhythm before the scheduled 
electrical cardioversion are reported at 0 J. The curves of the hvo 
patient groups are similar. The absolute zumber of patients with 
conversion at each energy step is shwn below the graph. 
43revimw studies. Earlier studies (12,15) reported that 
quinidine obtained reversion to sinus rhythm in 12% to 13% of 
patients before scheduled electrical cardioversion. The energy 
required for cardioversion was reported to be lowered (12,15) 
or at least not increased (13) by the drug, The incidence of 
atria1 premature beats after cardioversion was decreased 
(11,12,15), but serious arrhythmias-ventricular tachycardia or 
fibrillation-were reported after restoration of sinus rhythm 
(9,lO). Whether quinidine prevents very early recurrence of 
atria1 fibrillation is not known, although Rossi and Lawn (12) 
observed a nonsignificant trend supporting this assumption: 
Within 1 minute after cardioversion, 30% of patients who had 
received placebo and only 4% of those given quinidine had a 
recurrence of atriai fibrillation. 
Amiodarone obtained chemical cardioversion at a r&e 
similar to that of quinidine and did not raise the defibrillation 
threshold (10). Its intravenous use was associated with a higher 
incidence of postshock bradyarrhythmias (38.6% vs. 12%) and 
ventricular premature beats (14% vs. 4%) (10). Flecainide was 
repcrrted to significantly increase the energy required for 
Figure 3. Cumulative percent of patients in the placebo and 
propafenone groups submitted to direct current shock who had 
cardioversion at each energy level. The propafenone group is sepa- 
rated into those whose arrhythmia was transformed into atria1 flutter 
(AFI) and those with continued atrial fibrillation (AF). The absolute 
number of patients with conversion at cxh energ;, step is shown below 
the graph. 
too 
% 
50 
100 200 300 2nd 300 
placebo 40 47 40 5 
propafenone &F 4 41 12 3 
propafenone AFI 6 3 2 
100 
E 
F k 
9 
.g 
2? 
50 
-G- pPopafenone 
0 IOmin 24 hrs 48 R?S 
placebo 42 35 30 27 
propaf 41 41 39 36 
RR 0.47 0.34 
Cl 0.04-0.72 0.14-Q.M 
P 0.042 co.04 co.05 
Figure 4. The percent of each treatment group with sinus rhythm at 
the preestablished observation times. The curves are significantly 
different (p < 0.01). The absolute number of patients with atria1 
fibrillation recurrence, the relative risk of recurrence (RR) and the 
confidence intervals (CI) at the same preestablished times are shown 
below the graph. propaf = propafenone. 
cardioversion when given either orally (16) or intravenously 
(14), without affecting the success rate of the procedure (14). 
Propafenone effects OR DC shock efficacy and energy re- 
quirements. In our total group of patients, propafenone did 
not appear to have any significant effect on the total energy 
required for cardioversion or on the success rate of the 
procedure. In the patients pretreated with propafenone the 
effect of the drug on the defibrillation threshold was contra- 
dictory, depending on whether the ECG obtained immediately 
before DC shock showed atrial flutter or atria1 fibrillation. The 
energy required for cardioversion was significantly decreased 
in the patients who had atria1 fibrillation transformed into 
atria1 flutter by propafenone, whereas, in those with continued 
atria1 fibrillation, the required energy level tended to be higher 
than in the placebo group. This observation suggests that 
Table 3. Arrhythmic Complications Occurring Within 10 Minutes of 
Continuous Electrocardiographic Monitoring After Direct Current 
Shock in Patients With Cardioversion 
Placebo 
Group 
(II = 42) 
Propafenonr- 
Group P 
in = 38) Value 
Frequent or complex atrial 22 (52.4%) 7 (18.4%) 0.002 
premature beats 
Atria1 fibrillation relapse l(lb.70) 0 0.012 
Ventricular premature beats 6 (14.3%) I (2.6%) NS 
Sinus node disturbances 
Sinus bradycardia 0 2 (5.3%) NS 
(<45 beats/m&) 
Pauses (>2 s) 2 (4.8%) 6 (15.8%) NS 
Sinoatrial block 0 2 (5.3%) NS 
Junctional rhythm 1 (2.4%) 3 (7.9%) NS 
Total* 3 (7.1%) 11(28.9%) 0.017 
AV block 
1st degree 1 (2.4%) 3 (7.9%) N§ 
2nd degree 2 (4.8%) 1 (2.6%) 1% 
Total 3 (7.1%) 4 (10.5%) NS - 
*Some patients had more than one type of bradyarrhythmia. Data presented 
are number (%) of patients. 
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propafenone Ras a dual effect: a rise in defibrillation threshold 
that is often counterbalanced by the drug’s ability to “orga- 
nize” (22-24) the atria1 electrical activity, a condition in which 
less energy is usually required to terminate the arrhythmia 
(25). Indeed, it should be kept in mind that higher energy 
levels may be required for cardioversion in patients who have 
persistent atrial fibrillation while receiving propafenone. 
Atrial fibrillation recurrence. Propafenone decreased the 
incidence of frequent or complex atria1 premature beats after 
cardioversion and, most important, it reduced the likelihood of 
early recurrence of atria1 fibrillation. Indeed, in the very early 
minutes after cardioversion, atria1 fibrillation frequently re- 
curs, because atria1 irritability is high (as expressed by the 
frequency of atria1 premature beats) and the refractori periods 
of atria1 cells are still extremely short (26). Such arrhythmo- 
genie conditions explain why the effect of an antiarrhythmic 
agent is especially desirable in this period. 
The efficacy of propafenone in preventing early recurrence 
of atria1 fibrillation is also supported by the fact that all five 
placebo-treated patients who had early recurrence of the 
arrhythmia and undenvent a second cardioversion immediately 
after a boIus of intravenous propafenone were discharged with 
stable sinus rhythm. All five would otherwise have been 
considered resistant to cardioversion and their atria1 fibrilla- 
tion would have remained intact. 
This initial advantage in preserving sinus rhythm obtained 
by pretreatment with propafenone was maintained during 
in-hospital observation and the percent of patients with sinus 
.rhythm at 48 h was significantly higher in the patients who had 
r~eived the drug before cardioversion than in those who 
received it only immediately thereafter. 
Untoward effects. The increased incidence of posfcardio- 
version sinus node disturbances caused by propafenone, a 
finding already described with flecdinide (16) and a:miodarone 
(IO), can be related to the depressant action of the drug on the 
sinus node; this effect, although weak, can unmask latent sinus 
node dysfunction (27). Of importance, all excitation! 
conduction disturbances were asymptomatic. They were usu- 
ally transient and required no treatment, except in a few 
patients who needed a reduction in drug dosage and two who 
had a permanent pacemaker implanted, because the brady- 
arrhythmia persisted after drug discontinuation. 
Propafenone was usually well tolerated, but it ne:eded to be 
discontinued in 6.6% of patients because of adverse effects. As 
with other class I drugs, serious side effects often occur within 
the first days of drug administration, thus suggesting that it is 
preferable to in&We such therapy during a hospital stay. 
Clinical implicaiians. Our results indicate that itreatment 
with oral propafenone before electrical cardioversion is pref- 
erable to starting treatment after reversion to sinurs rhythm, 
because pretreatment with propafenone reduces early recur- 
rence of the arrhythmia, thus allowing more patients to be 
discharged with sinus rhythm. This advantage is countarbal- 
aneed by the cost of admitting patients to the hospital some 
days before cardioversion to start the antiarrhythmic therapy. 
A more cost-effective strategy might be to administer the drug 
intravenously just before the DC shock and then continue with 
oral administration. Alternatively, intravenous propafenone 
loading might be given immediately after delivery of the DC 
shock. However, this strategy might not be optimal, because- 
owing to the lag between drug administration and its electro- 
physiologic ettect-the anti~~rrhyt~lmi~ action of the drag 
would be foregone, just in the immediate period after cardio- 
version, when the risk of the arrhythmia recurrence is maximal. 
However, none of the two aforementioned alternatives is 
directly supported by our data, and further studies would be 
required to assess their validity. 
Conclusions. Tlle results of this study support the accumu- 
lating evidence that electrical cardioversion of chronic atria1 
fibrillation should be preceded by ihc administration of an 
antiarrhythmic drug. In this setting, propafenone, despite a 
direct action that seems to increase the energy required for 
atria1 defibrillation, actually decreases it in a substantial pro- 
portion of patients, by transforming the original arrhythmia 
into atria1 flutter. On balance, both the energy required for 
cardioversion and the immediate success rate of the procedure 
are not affected by the drug. Moreover, pretreatment with 
propafenone significantly decreases the postcardioversion in- 
cidence of complex premature supraventricular beats as well as 
the early recurrence of atria1 fibrillation, thus improving the 
likelihood of maintenance of sinus rh@hm, at least in a 
short-term follow-up period. 
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